Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while Sana Biotechnology Inc trades at $2.33 (market cap $697.51M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 4× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (2,763,583 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| DYN | SANA | |
|---|---|---|
Market Cap | $2.81B | $697.51M |
Volume | 2,195,902 | 2,763,583 |
Sector | Health | Health |
52-Week High | $26.78 | $5.92 |
52-Week Low | $14.60 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $2.13B | $610.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Sana Biotechnology (SANA) trades at $2.41, down 8.02% in the last session, reflecting a bearish technical trend despite bullish oscillators. The company is pre-revenue with significant losses, reporting a net income of -$244.17 million in 2025 and negative cash flow, while maintaining a price-to-book ratio of 4.51. Recent news highlights active participation in investor conferences and a positive analyst consensus.
The outlook is speculative, with high risk due to no current revenue and substantial cash burn, but potential upside exists if clinical developments succeed, supported by an analyst consensus price target of $8.50. Key risks include funding needs, clinical trial outcomes, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
